PD-1/PD-L1 inhibitors have been applied in melanoma, non-small cell lung cancer (NSCLC)10,11 and renal cancer12, and have achieved certain effects, but their broader applicability is not extensive. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.